Region 7 Healthcare Coalition
  • Home
    • Response Platforms
    • Important Links
    • Public Health Emergency
    • State of Michigan
  • About
    • Region 7 Staff
  • Events
  • Resources
  • Partners
  • Contact
    • Feedback
  • COVID-19
    • Resource Requests
    • Non-Healthcare Resources

Alerts

CDC HAN404: Patients Receiving Eculizumab at High Risk for Meningococcal Disease Despite Vaccination

7/10/2017

 
Message Details
Date Sent: 07/07/2017 12:26 PM EDT
Sender: Michigan Health Alert Network
Subject: CDC HAN404: Patients Receiving Eculizumab at High Risk for Meningococcal Disease Despite Vaccination
Message:
Summary
Eculizumab (Soliris®) recipients have a 1,000 to 2,000-fold greater risk of invasive meningococcal disease compared to the general U.S. population. The Food and Drug Administration (FDA)-approved prescribing information for eculizumab includes a black box warning for increased risk of meningococcal disease, and the Advisory Committee on Immunization Practices (ACIP) recommends meningococcal vaccination for all patients receiving eculizumab. Recent data show that some patients receiving eculizumab who were vaccinated with the recommended meningococcal vaccines still developed meningococcal disease, most often from nongroupable Neisseria meningitidis, which rarely causes invasive disease in healthy individuals.

Recommendations for Healthcare Providers
Healthcare Providers:
  • Could consider antimicrobial prophylaxis for the duration of eculizumab therapy to potentially reduce the risk of meningococcal disease.
  • Should continue meningococcal vaccination of all patients who receive eculizumab.
  • Should administer meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risks of developing a meningococcal infection, according to the product label.
  • Should maintain a high index of suspicion for meningococcal disease in patients taking eculizumab who present with any symptoms consistent with either meningitis or meningococcemia, even if the patient’s symptoms initially appear mild, and irrespective of the patient’s meningococcal vaccine or antimicrobial prophylaxis status.
Background
Eculizumab is most commonly prescribed for treatment of 2 rare blood disorders: atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Through a request for data on meningococcal disease cases reported to state health departments, the U.S. Centers for Disease Control and Prevention (CDC) identified 16 cases of meningococcal disease in eculizumab recipients in the United States from 2008 through 2016; 11 (69%) of these were caused by nongroupable N. meningitidis. Meningococcal conjugate (MenACWY) vaccine targets serogroups A, C, W, and Y, and provides no protection against nongroupable N. meningitidis. Serogroup B meningococcal (MenB) vaccines are licensed specifically for protection against serogroup B meningococcal disease. Researchers have not assessed the extent of any potential cross protection for nongroupable N. meningitidis strains.

For More Information
  • Managing the Risk of Meningococcal Disease among Patients Who Receive Eculizumab Therapy
  • Signs and Symptoms of Meningococcal Disease
  • Food and Drug Administration. Soliris® (eculizumab) product label
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Child and Adolescent Indications Schedule: Vaccines That Might Be Indicated for Persons Aged 0 through 18 Years Based On Medical Indications
  • Adult Immunization Schedule by Medical and Other Indications Recommended Immunization Schedule for Adults Aged 19 Years or Older by Medical Conditions and Other Indications, United States, 2017
-- This alert is being sent to the following statewide MIHAN roles: Communicable Disease / Infection Prevention | Emergency Preparedness | Epidemiology | HAN Coordinator | Healthcare | Health Officer | Laboratory | Physician / Medical Director --

Attachments:
  • HAN 404 Meningococcal Disease Despite Vaccination.pdf


Comments are closed.

    CDC Alerts

    For Nationwide Alerts, please click on one of the archive links below. 
    2014 Alerts     
    2013 Alerts 
    2012 Alerts     
    ​
    2011 Alerts

    Archives

    August 2017
    July 2017
    May 2017
    April 2017
    January 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    June 2015
    May 2015
    January 2015
    December 2014
    November 2014
    July 2014
    June 2014
    May 2014

    Categories

    All
    Agriculture /Animal Health
    ASPR TRACIE
    Centers For Disease Control
    Children
    Communicable Disease / Infection Prevention
    Communications / Public Information
    Community Health Emergency Coordination Center (CHECC)
    Cyber Security
    Drug Enforcement Administration
    Ebola
    Elderly
    Emergency Management
    Emergency Preparedness
    Emergency Room
    Environmental
    Epidemiology
    FBI
    First Responders
    Food And Drug Administration
    HAN Coordinator
    Health And Human Services (HHS)
    Healthcare
    Health Officer
    Hospital
    Infectious Disease
    Influenza
    Laboratory
    Law Enforcement
    Local Health Department
    Medical Director
    Michigan Department Of Health And Human Services
    Michigan Department Of Health And Human Services
    Michigan Departments Of Agriculture And Rural Development
    Michigan Poison Control Center
    Michigan Regional Poison Center
    National Guard
    Neurology
    Physician
    Pregnancy
    Primary Care
    Public Health
    Public Information Officers
    Recalls
    Reports
    Security/Public Safety/ Military
    State Guidance
    Technology
    US Dept. Of Agriculture
    Vaccines
    Viral Illness
    World Health Organization

    RSS Feed

To activate the Region 7
Medical Coordination Center call:


Gaylord Regional
Communication Center
1-989-732-5141

​

During your call, include the following information: 
- Your name and contact number.
- Your agency or hospital.
- The reason for requesting the resource.
- Exact location to where you need the resource delivered.
- Who will accept and sign for the resource.

Site Map

Home
Important links
Public Health Emergency
Michigan.gov
Events
Newsroom
Alerts
Newsletter
Members
Partner Resources

Organization

About
Blog
Contact
web counter
web counter
R7HCC logo
Copyright © 2014 | 2464 Silver Fox Trail Suite A, Gaylord MI 49735 | 989.748.4975
  • Home
    • Response Platforms
    • Important Links
    • Public Health Emergency
    • State of Michigan
  • About
    • Region 7 Staff
  • Events
  • Resources
  • Partners
  • Contact
    • Feedback
  • COVID-19
    • Resource Requests
    • Non-Healthcare Resources